The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer

Oncologist

Volumn 6, Issue 1, 2001, Pages 56-64

  Blum, Joanne L ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Breast cancer; Capecitabine; Colorectal cancer; Docetaxel; Oral fluoropyrimidine; Paclitaxel; Taxane resistant; Thymidine phosphorylase

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERANCE; DRUG USE; HUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; DEOXYCYTIDINE; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 0035133449     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-1-56     Document Type: Article

References (35)

1. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
2. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
3. Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors
4. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
5. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
6. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
7. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models
8. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (xeloda) in human cancer xenografts
9. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
10. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
11. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
12. A human capecitabine excretion balance and pharmaco-kinetic study after administration of a single oral dose of 14C-labelled drug
13. Capecitabine: A review of its clinical pharmacokinetics
14. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients
15. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
16. Influence of the antacid maalox on the pharmacokinetics of capecitabine in cancer patients
17. Capecitabine (Xeloda), an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
18. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
19. A multicenter phase II trial of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer
20. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
21. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
22. A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged ≥55 years
23. First-line capecitabine treatment for metastatic breast cancer (MBC): Updated data from a randomized phase II trial
24. Phase I and pharmacokinetic study of the oral fluoropyrimidine carbamate capecitabine in combination with paclitaxel in patients with advanced solid malignancies
25. Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer
26. A matrix-designed phase I dose-finding and pharmacokinetic study of the combination of capecitabine (Xeloda™) and docetaxel (Taxotere™) in patients with advanced solid tumours
27. Dose finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated advanced breast cancer patients
28. Phase I study of vinorelbine (V) and capecitabine (C) in advanced breast cancer (ABC)
29. A phase III trial of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer
30. A phase III trial (SO14796) of Xeloda™ (capecitabine) in previously untreated advanced metastatic colorectal cancer
31. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine)
32. Patient preferences for oral versus intravenous palliative chemotherapy
33. A study of quality of life in cancer patients receiving palliative chemotherapy
34. A randomized crossover trial comparing UFT (uracil/tegafur) + leucovorin (LV) and intravenous flourouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer
35. Results of a large phase III trial of Xeloda™/Taxotere™ combination therapy vs Taxotere monotherapy in metastatic breast cancer (MBC) patients